Cell Therapy Deals A "Strategic Priority" For Shire
This article was originally published in Pharmaceutical Approvals Monthly
The recent earnings season was a reminder that Shire PLC, along with other specialist drug developers such as Celgene Inc., are comfortably positioned in a high-revenue-growth world that most big pharma have forgotten about.
You may also be interested in...
Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.
The evening before Advanced BioHealing Inc. was set to debut on the New York Stock Exchange on May 18, it announced that Shire PLC has agreed to buy it for $750 million.
The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.